Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas

Central Hospital, Nancy, France120 enrolled

Overview

Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

120

Conditions

Pancreas Adenocarcinomas

Interventions

Magnetic resonance elastography (MRE).DEVICE

Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure

High-resolution diffusion sequence in MRIDEVICE

High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT; * Adult patient: age ≥ 18 years; * Patient affiliated with a social security system or beneficiary of such a system; * Patient who has received complete information about the research organization and has signed an informed consent form. Exclusion Criteria: * Patient with a contraindication to MRI. * Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code. * Pregnant woman, parturient, or breastfeeding mother; * Minor (non-emancipated) individual; * Adult individual under legal protection (guardianship, curatorship, or judicial safeguard); * Adult individual unable to express consent. * Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.

Locations (1)

CHRU Nancy

Vandœuvre-lès-Nancy, France, France

RECRUITING

Outcomes

Primary Outcomes

Absolute elasticity value of the tumor (kPa) before treatment.

The absolute elasticity value of the tumor corresponds to the average elasticity value measured within the region of interest, which will be outlined according to the tumor's boundaries.

Time frame: Baseline (J0) before treatment

Absolute elasticity value of the tumor (kPa) after chemotherapy.

The absolute elasticity value of the tumor corresponds to the average elasticity value measured within the region of interest, which will be outlined according to the tumor's boundaries.

Time frame: 3 months, after chimiotherapy

Secondary Outcomes

For patient with a resectable pancreatic lesion, evaluation of the association between size of the tumor (mm) with the absolute elasticity value of the tumor (kPa).

Time frame: 3 months, after surgery

For the patients who underwent surgery, evaluation of the association between size of the tumor (mm) and the absolute elasticity value of the tumor (kPa) before chimiotherapy.

Time frame: 6 months, after surgery

For the patients who underwent surgery, evaluation of the association between size of the tumor (mm) and the absolute elasticity value of the tumor (kPa) after chimiotherapy..

Time frame: 6 months, after surgery

For patient with a resectable pancreatic lesion, evaluation of the association between size of the tumor (mm) with the apparent coefficient diffusion (ADC) in mm²/s.

Time frame: 3 months, after surgery

For the patients who underwent surgery, evaluation of the association between size of the tumor (mm) with the apparent coefficient diffusion (ADC) in mm²/s before chimiotherapy..

Central Contacts

Guillaume DROUOT, PhD

CONTACT

0385157666 g.drouot@chru-nancy.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.